Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as meningococcal ACWY (vaccine)
meningococcal ACWY · 1 trial · 1 indication
Response to vaccine antigen was defined as: for initially seronegative subjects \[subjects with serum bactericidal assay using rabbit complement (rSBA) titer lower than (\<) 1:8, post-vaccination rSBA titer greater than or equal to (≥) 1:32\] and for initially seropositive (subjects with rSBA titer ≥ 1:8), at least 4-fold increase in rSBA titer from pre to post vaccination.
Local symptom, Grade 3 = pain that prevented normal activity and redness/ swelling spreading beyond (\>) 50 millimeters (mm). General symptom, Grade 3 = symptom that prevented normal activity and fever (orally) \>39.5 °C.
| Arm | Type | Description |
|---|---|---|
| Nimenrix Group | EXPERIMENTAL | Subjects receiving GSK Biologicals' meningococcal vaccine 134612 |
| Mencevax Group | ACTIVE_COMPARATOR | Subjects receiving Mencevax™ ACWY |
| Name | Type | Description |
|---|---|---|
| meningococcal ACWY (vaccine) | BIOLOGICAL | One intramuscular dose. |
| Mencevax™ ACWY | BIOLOGICAL | One subcutaneous dose. |
Inclusion Criteria: * Subjects who the investigator believes that they and/or their parents/ legally acceptable representative can and will comply with the requirements of the protocol. * A male or female between, and including, 11 and 55 years of age at the time of vaccination. * Written informed ...
Meningococcal ACWY is a vaccine being developed by GSK plc for the prevention of meningococcal infections. It is designed to protect against meningococcal serogroups A, C, W, and Y. The vaccine is in Phase 2 clinical development and has been studied in adolescents and adults.
Meningococcal ACWY is intended for the prevention of infections caused by meningococcal bacteria, specifically serogroups A, C, W, and Y. It is being evaluated in adolescents and adults, including healthy volunteers. The vaccine targets the infectious disease therapeutic area.
Meningococcal ACWY is developed by GSK plc, which trades under the ticker GSK. GSK conducted a Phase 2 study of the vaccine in adolescents and adults to evaluate non-inferiority and persistence of immune response up to five years.
Meningococcal ACWY is in Phase 2 clinical development. It is an investigational vaccine and is not approved. One Phase 2 trial has been completed, and no trials are currently active. The completed study enrolled 500 participants.
Meningococcal ACWY has been studied in one completed Phase 2 trial, NCT00356369, titled a study in adolescents and adults to evaluate non-inferiority and persistence up to five years of the GSK Bio MenACWY conjugate vaccine. The trial enrolled 500 participants across the Philippines and Saudi Arabia.
Yes, meningococcal ACWY is also known as meningococcal ACWY (vaccine). Both names refer to the same GSK plc vaccine candidate for meningococcal serogroups A, C, W, and Y, which is in Phase 2 development for the prevention of meningococcal infections.